Table 2 Cabozantinib treatment details
From: Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
Overall (n = 59) | Dose reductionb (n = 34) | No dose reductionb(n = 25) | |
|---|---|---|---|
Treatment duration (weeks) | 34 (4–204) | 46 (8–204) | 23 (4–173) |
Average daily dose (mg) | 38 (12–60) | 32 (12–56) | 40 (20–60) |
Initiation dose (mg) | |||
60 | 27 (46) | 21 (62) | 6 (24) |
40 | 25 (42) | 12 (37) | 13 (52) |
20 | 7 (12) | 1 (3) | 6 (24) |
Best tolerated dose in mg | 40 (10–60) | 30 (10–50) | 40 (20–60) |
60 | 7 (12) | 0 (0) | 7 (28) |
50a | 2 (3) | 1 (3) | 1 (4) |
40 | 27 (46) | 12 (36) | 15 (60) |
26–31a | 7 (12) | 7 (21) | 0 |
20 | 15 (25) | 13 (38) | 2 (8) |
10a | 1 (2) | 1 (3) | 0 |
Treatment discontinuation | 41 (70) | 19 (56) | 22 (88) |
Progressive disease | 29 (49) | 15 (43) | 16 (54) |
Toxicity | 9 (15) | 4 (11) | 5 (20) |
Other | 3 (5) | 2 (6) | 1 (4) |